Patient-Reported (EORTC QLQ-CIPN20) Versus Physician-Reported (CTCAE) Quantification of Oxaliplatin- and Paclitaxel/Carboplatin-Induced Peripheral Neuropathy in NCCTG/Alliance Clinical Trials

समान संसाधन

• Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance)
  द्वारा: Boora, Ganesh K., और अन्य
  प्रकाशित: (2016)
• The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA
  द्वारा: Wolf, Sherry L., और अन्य
  प्रकाशित: (2011)
• Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire
  द्वारा: Lavoie Smith, Ellen M., और अन्य
  प्रकाशित: (2013)
• Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire–Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data
  द्वारा: Smith, Ellen M. Lavoie, और अन्य
  प्रकाशित: (2018)
• Translation and validation of the EORTC brain cancer module (EORTC QLQ-BN20) for use in Iran
  द्वारा: Khoshnevisan, Alireza, और अन्य
  प्रकाशित: (2012)